• MEI Pharma, KHK to develop and commercialize ME-401 biospectrumasia
    November 26, 2018
    MEI Pharma, Inc. and Kyowa Hakko Kirin Co., Ltd. (KHK), have announced the execution of a license agreement granting KHK exclusive rights to develop and commercialize ME-401 in Japan.
PharmaSources Customer Service